NVAX Share Price

Open 1.55 Change Price %
High 1.56 1 Day -0.05 -3.21
Low 1.49 1 Week 0.17 12.69
Close 1.51 1 Month 0.09 6.34
Volume 7617052 1 Year -3.35 -68.93
52 Week High 8.49
52 Week Low 1.16
NVAX Important Levels
Resistance 2 1.57
Resistance 1 1.55
Pivot 1.52
Support 1 1.47
Support 2 1.45
NASDAQ USA Most Active Stocks
FNFG 10.18 -0.20%
ASTI 0.00 0.00%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
ACAS 17.99 0.39%
CSCO 33.72 0.36%
More..
NASDAQ USA Top Gainers Stocks
EDMC 0.02 100.00%
LIWA 0.02 100.00%
QKLS 0.20 100.00%
MOSY 3.50 54.19%
LOCM 0.09 50.00%
MYRX 0.06 50.00%
LMIA 13.66 48.64%
CPSL 0.10 42.86%
WRES 0.09 28.57%
BSDM 0.62 26.53%
More..
NASDAQ USA Top Losers Stocks
GPRC 0.00 -100.00%
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
QTWW 0.08 -50.00%
SPIR 0.01 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
More..

Novavax, Inc. (NASDAQ: NVAX)

NVAX Technical Analysis 2
As on 17th Feb 2017 NVAX Share Price closed @ 1.51 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 4.13 & Buy for SHORT-TERM with Stoploss of 1.36 we also expect STOCK to react on Following IMPORTANT LEVELS.
NVAX Target for February
1st Target up-side 1.46
2nd Target up-side 1.56
3rd Target up-side 1.66
1st Target down-side 1.16
2nd Target down-side 1.06
3rd Target down-side 0.96
NVAX Other Details
Segment EQ
Market Capital 253984256.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.novavax.com
NVAX Address
NVAX
20 Firstfield Road
Gaithersburg, MD 20878
United States
Phone: 240-268-2000
NVAX Latest News
Interactive Technical Analysis Chart Novavax, Inc. ( NVAX NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Novavax, Inc.
NVAX Business Profile
Novavax, Inc. (Novavax) is a clinical stage biopharmaceutical company. The Company focuses on developing recombinant vaccines. The Company�s technology platform is based on recombinant vaccine technology that includes the virus-like particles (VLPs). The Company's vaccine candidates are genetically engineered three-dimensional nanostructures, which incorporate immunologically important recombinant proteins. In July 2013, Novavax acquired approximately 97.4% of shares in Isconova AB.